FeesSafety
Pluang+

iShares Flexible Income Active ETF rated Buy for 7.12% yield and strong income cushion with 3.7-year duration.

Market News
15 Sep 2026
Seeking Alpha
View Source
Bullish
iShares Flexible Income Active ETF rated Buy for 7.12% yield and strong income cushion with 3.7-year duration.

The iShares Flexible Income Active ETF (BINC) has received a Buy rating due to its attractive 7.12% yield to maturity (YTM) and a moderate duration of 3.7 years, providing a solid income buffer. The fund focuses on diversified, credit-sensitive bonds with controlled duration rather than deep-value bonds, accepting risks like recession sensitivity and negative convexity. Its simulated median annualized return is 5.9% over three years, outperforming similar duration Treasuries and broad benchmarks after fees. Key factors supporting this outlook include elevated Treasury yields, effective default risk management, and manager flexibility, while risks involve spread repricing, credit losses, and potential underperformance against benchmarks.

The iShares Flexible Income Active ETF (BINC) offers an attractive 7.12% yield to maturity, highlighting its income potential. For readers following US stocks, here is Pluang's market snapshot as of Sep 15, 2026 12:11 WIB: out of 150 priced US stocks tradable on Pluang, 44 rose and 98 fell today. Notable movers include GSK at USD 50.22 (+4.34%), HPQ at USD 34.04 (-4.06%), and COIN at USD 184.65 (-3.55%).

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
46 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App